A-172 |
Growth Inhibition Assay |
10 nM |
24/48 h |
|
inhibits cell growth time dependently |
26150340 |
U87MG |
Growth Inhibition Assay |
10 nM |
24/48 h |
|
inhibits cell growth time dependently |
26150340 |
Hbl-1 |
Growth Inhibition Assay |
|
48 h |
|
IC50=1.6 μM |
26116270 |
OCI-Ly10 |
Growth Inhibition Assay |
|
48 h |
|
IC50=0.9 μM |
26116270 |
Riva |
Growth Inhibition Assay |
|
48 h |
|
IC50=2.2 μM |
26116270 |
Su-DHL2 |
Growth Inhibition Assay |
|
48 h |
|
IC50=3.3 μM |
26116270 |
OCI-Ly1 |
Growth Inhibition Assay |
|
48 h |
|
IC50=2.4 μM |
26116270 |
OCI-Ly7 |
Growth Inhibition Assay |
|
48 h |
|
IC50=1.2 μM |
26116270 |
Su-DHL4 |
Growth Inhibition Assay |
|
48 h |
|
IC50=4.7 μM |
26116270 |
Su-DHL6 |
Growth Inhibition Assay |
|
48 h |
|
IC50=3.2 μM |
26116270 |
Hbl-2 |
Growth Inhibition Assay |
|
48 h |
|
IC50=1.9 μM |
26116270 |
Jeko-1 |
Growth Inhibition Assay |
|
48 h |
|
IC50=1.5 μM |
26116270 |
Jvm-2 |
Growth Inhibition Assay |
|
48 h |
|
IC50=4.0 μM |
26116270 |
Rec-1 |
Growth Inhibition Assay |
|
48 h |
|
IC50=2.3 μM |
26116270 |
CCL-119 |
Growth Inhibition Assay |
|
48 h |
|
IC50=1.7 μM |
26116270 |
H9 |
Growth Inhibition Assay |
|
48 h |
|
IC50=1.2 μM |
26116270 |
HH |
Growth Inhibition Assay |
|
48 h |
|
IC50=2.5 μM |
26116270 |
Sup-T1 |
Growth Inhibition Assay |
|
48 h |
|
IC50=1.6 μM |
26116270 |
MM.1S |
Function Assay |
0-5μM |
6 h |
|
increases acetylated α-tubulin |
22262760 |
MM.1S |
Function Assay |
0.25/1μM |
18 h |
|
increases acetylated α-tubulin |
22262760 |
MM.1R |
Function Assay |
0.25/1μM |
18 h |
|
increases acetylated α-tubulin |
22262760 |
RPMI8226 |
Function Assay |
0.25/1μM |
18 h |
|
increases acetylated α-tubulin |
22262760 |
MM.1S |
Cell Viability Assay |
0-8μM |
48 h |
|
decreases MM-cell viability in a dose-dependent manner |
22262760 |
OPM1 |
Cell Viability Assay |
0-8μM |
48 h |
|
decreases MM-cell viability in a dose-dependent manner |
22262760 |
RPMI |
Cell Viability Assay |
0-8μM |
48 h |
|
decreases MM-cell viability in a dose-dependent manner |
22262760 |
MM.1R |
Cell Viability Assay |
0-8μM |
48 h |
|
decreases MM-cell viability in a dose-dependent manner |
22262760 |
LR5 |
Cell Viability Assay |
0-8μM |
48 h |
|
decreases MM-cell viability in a dose-dependent manner |
22262760 |
OPM2 |
Cell Viability Assay |
0-8μM |
48 h |
|
decreases MM-cell viability in a dose-dependent manner |
22262760 |
Sf9 |
Function assay |
|
10 mins |
|
Inhibition of full length human recombinant N-terminal GST-tagged HDAC6 expressed in Sf9 cells using FTS as substrate preincubated for 10 mins followed by substrate addition measured over 30 mins, IC50 = 0.0047 μM. |
28038324 |
Sf9 |
Function assay |
|
15 mins |
|
Inhibition of full length recombinant human N-terminal GST-tagged HDAC6 expressed in baculovirus infected sf9 cells using Boc-Lys-(Ac)-AMC as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by fluorescence assay, IC50 = 0.009 μM. |
29500130 |
Sf9 |
Function assay |
|
15 mins |
|
Inhibition of full length recombinant human C-terminal His-tagged HDAC3/N-terminal GST-tagged NCOR2 (395 to 489 residues) expressed in baculovirus infected sf9 cells using Boc-Lys-(Ac)-AMC as substrate preincubated for 15 mins followed by substrate additi, IC50 = 0.037 μM. |
29500130 |
Sf9 |
Function assay |
|
10 mins |
|
Inhibition of full length human recombinant C-terminal FLAG-tagged HDAC2 expressed in Sf9 cells using FTS as substrate preincubated for 10 mins followed by substrate addition measured over 30 mins, IC50 = 0.048 μM. |
28038324 |
Sf9 |
Function assay |
|
10 mins |
|
Inhibition of full length human recombinant C-terminal FLAG-His-tagged HDAC1 expressed in Sf9 cells using FTS as substrate preincubated for 10 mins followed by substrate addition measured over 30 mins, IC50 = 0.058 μM. |
28038324 |
Sf9 |
Function assay |
|
15 mins |
|
Inhibition of full length recombinant human C-terminal His-tagged HDAC2 expressed in baculovirus infected sf9 cells using Boc-Lys-(Ac)-AMC as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by fluorescence assay, IC50 = 0.066 μM. |
29500130 |
Sf9 |
Function assay |
|
15 mins |
|
Inhibition of full length recombinant human C-terminal FLAG/His-tagged HDAC1 expressed in baculovirus infected sf9 cells using Boc-Lys-(Ac)-AMC as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by fluorescence ass, IC50 = 0.1 μM. |
29500130 |
BCP-ALL |
Cytotoxicity assay |
|
72 hrs |
|
Cytotoxicity against human BCP-ALL cells derived from patient 1 after 72 hrs by CellTiter-Glo luminescent cell viability assay, IC50 = 0.29 μM. |
30365892 |
BCP-ALL |
Cytotoxicity assay |
|
72 hrs |
|
Cytotoxicity against human BCP-ALL cells derived from patient 4 after 72 hrs by CellTiter-Glo luminescent cell viability assay, IC50 = 0.54 μM. |
30365892 |
BCP-ALL |
Cytotoxicity assay |
|
72 hrs |
|
Cytotoxicity against human BCP-ALL cells derived from patient 2 after 72 hrs by CellTiter-Glo luminescent cell viability assay, IC50 = 0.58 μM. |
30365892 |
RPMI8226 |
Cytotoxicity assay |
|
72 hrs |
|
Cytotoxicity against human RPMI8226 cells after 72 hrs by MTT assay, IC50 = 1.468 μM. |
26443078 |
SEM |
Cytotoxicity assay |
|
72 hrs |
|
Cytotoxicity against human SEM cells after 72 hrs by CellTiter-Glo luminescent cell viability assay, IC50 = 1.61 μM. |
30365892 |
SUP-B15 |
Cytotoxicity assay |
|
72 hrs |
|
Cytotoxicity against human SUP-B15 cells after 72 hrs by CellTiter-Glo luminescent cell viability assay, IC50 = 1.92 μM. |
30365892 |
RPMI18226 |
Cytotoxicity assay |
|
72 hrs |
|
Cytotoxicity against human RPMI18226 cells after 72 hrs by CellTiter-Glo luminescent cell viability assay, IC50 = 1.97 μM. |
30365892 |
HL60 |
Cytotoxicity assay |
|
72 hrs |
|
Cytotoxicity against human HL60 cells after 72 hrs by CellTiter-Glo luminescent cell viability assay, IC50 = 2.36 μM. |
30365892 |
HL60 |
Antiproliferative assay |
|
48 hrs |
|
Antiproliferative activity against human HL60 cells after 48 hrs in presence of JAK2 inhibitor CYT-387 by CCK-8 assay, IC50 = 2.54 μM. |
29940115 |
K562 |
Antiproliferative assay |
|
48 hrs |
|
Antiproliferative activity against human K562 cells after 48 hrs in presence of JAK2 inhibitor CYT-387 by CCK-8 assay, IC50 = 2.54 μM. |
29940115 |
HEL |
Antiproliferative assay |
|
48 hrs |
|
Antiproliferative activity against human HEL cells after 48 hrs in presence of JAK2 inhibitor CYT-387 by CCK-8 assay, IC50 = 2.54 μM. |
29940115 |
KCL22 |
Cytotoxicity assay |
|
72 hrs |
|
Cytotoxicity against imatinib-resistant human KCL22 cells after 72 hrs by CellTiter-Glo luminescent cell viability assay, IC50 = 3.38 μM. |
30365892 |
U266 |
Cytotoxicity assay |
|
72 hrs |
|
Cytotoxicity against human U266 cells after 72 hrs by CellTiter-Glo luminescent cell viability assay, IC50 = 3.52 μM. |
30365892 |
SUP-B15 |
Cytotoxicity assay |
|
72 hrs |
|
Cytotoxicity against imatinib-resistant human SUP-B15 cells after 72 hrs by CellTiter-Glo luminescent cell viability assay, IC50 = 3.54 μM. |
30365892 |
KCL22 |
Cytotoxicity assay |
|
72 hrs |
|
Cytotoxicity against human KCL22 cells after 72 hrs by CellTiter-Glo luminescent cell viability assay, IC50 = 3.75 μM. |
30365892 |
HL60 |
Antiproliferative assay |
|
48 hrs |
|
Antiproliferative activity against human HL60 cells after 48 hrs by CCK-8 assay, IC50 = 3.75 μM. |
29940115 |
K562 |
Antiproliferative assay |
|
48 hrs |
|
Antiproliferative activity against human K562 cells after 48 hrs by CCK-8 assay, IC50 = 3.75 μM. |
29940115 |
HEL |
Antiproliferative assay |
|
48 hrs |
|
Antiproliferative activity against human HEL cells after 48 hrs by CCK-8 assay, IC50 = 3.75 μM. |
29940115 |
BCP-ALL |
Cytotoxicity assay |
|
72 hrs |
|
Cytotoxicity against human BCP-ALL cells derived from patient 3 after 72 hrs by CellTiter-Glo luminescent cell viability assay, IC50 = 4.45 μM. |
30365892 |
MV4-11 |
Function assay |
1000 nM |
6 hrs |
|
Inhibition of HDAC1/2/3 in human MV4-11 cells assessed as upregulation of histone H3 acetylation at 1000 nM after 6 hrs by Western blot analysis |
26443078 |
TC32 |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells |
29435139 |
DAOY |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells |
29435139 |
SJ-GBM2 |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells |
29435139 |
A673 |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells |
29435139 |
SK-N-MC |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells |
29435139 |
BT-37 |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells |
29435139 |
NB-EBc1 |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells |
29435139 |
Saos-2 |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells |
29435139 |
SK-N-SH |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells |
29435139 |
NB1643 |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells |
29435139 |
LAN-5 |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells |
29435139 |
BT-12 |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells |
29435139 |
Rh18 |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells |
29435139 |
OHS-50 |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells |
29435139 |
RD |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells |
29435139 |
MG 63 (6-TG R) |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells |
29435139 |
Rh30 |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells |
29435139 |
Rh41 |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells |
29435139 |
HL60 |
Function assay |
0.1 to 10 uM |
24 hrs |
|
Inhibition of HDAC6 in human HL60 cells assessed as increase in acetyl-alpha tubulin expression at 0.1 to 10 uM after 24 hrs by immunoblot assay |
30365892 |
SEM |
Function assay |
0.1 to 10 uM |
24 hrs |
|
Inhibition of HDAC6 in human SEM cells assessed as increase in acetyl-alpha tubulin expression at 0.1 to 10 uM after 24 hrs by immunoblot assay |
30365892 |
SUP-B15 |
Function assay |
0.1 to 10 uM |
24 hrs |
|
Inhibition of HDAC6 in imatinib-resistant human SUP-B15 cells assessed as increase in acetyl-alpha tubulin expression at 0.1 to 10 uM after 24 hrs by immunoblot assay |
30365892 |
HL60 |
Function assay |
0.1 to 10 uM |
24 hrs |
|
Inhibition of HDAC6 in human HL60 cells assessed as increase in acetyl-histone H3 expression at 0.1 to 10 uM after 24 hrs by immunoblot assay |
30365892 |
SEM |
Function assay |
0.1 to 10 uM |
24 hrs |
|
Inhibition of HDAC6 in human SEM cells assessed as increase in acetyl-histone H3 expression at 0.1 to 10 uM after 24 hrs by immunoblot assay |
30365892 |
SUP-B15 |
Function assay |
0.1 to 10 uM |
24 hrs |
|
Inhibition of HDAC6 in imatinib-resistant human SUP-B15 cells assessed as increase in acetyl-histone H3 expression at 0.1 to 10 uM after 24 hrs by immunoblot assay |
30365892 |
HL60 |
Function assay |
0.1 to 10 uM |
24 hrs |
|
Inhibition of HDAC6 in human HL60 cells assessed as increase in cleaved PARP expression at 0.1 to 10 uM after 24 hrs by immunoblot assay |
30365892 |
SEM |
Function assay |
0.1 to 10 uM |
24 hrs |
|
Inhibition of HDAC6 in human SEM cells assessed as increase in cleaved PARP expression at 0.1 to 10 uM after 24 hrs by immunoblot assay |
30365892 |
SUP-B15 |
Function assay |
0.1 to 10 uM |
24 hrs |
|
Inhibition of HDAC6 in imatinib-resistant human SUP-B15 cells assessed as increase in cleaved PARP expression at 0.1 to 10 uM after 24 hrs by immunoblot assay |
30365892 |
SEM |
Antiproliferative assay |
|
24 to 72 hrs |
|
Antiproliferative activity against human SEM cells at IC50 to 2 times IC50 after 24 to 72 hrs by trypan exclusion method |
30365892 |
HEL |
Cell cycle assay |
1 to 10 uM |
48 hrs |
|
Cell cycle arrest in human HEL cells assessed as accumulation at G1 phase at 1 to 10 uM after 48 hrs propidium iodide staining based flow cytometry |
29940115 |
SEM |
Function assay |
|
18 hrs |
|
Inhibition of HDAC6 in human SEM cells assessed as decrease in aggresome accumulation at IC50 after 18 hrs by fluorescence microscopic method |
30365892 |
SEM |
Function assay |
1.6 uM |
18 hrs |
|
Inhibition of HDAC6 in human SEM cells assessed as decrease in aggresome accumulation at 1.6 uM after 18 hrs by FACS analysis |
30365892 |
SH-SY5Y |
Function assay |
0.1 to 1 uM |
24 hrs |
|
Inhibition of HDAC6 in human SH-SY5Y cells assessed as increase in acetylation of alpha-tubulin at 0.1 to 1 uM after 24 hrs by Western blot analysis |
30028616 |
SH-SY5Y |
Function assay |
0.1 to 1 uM |
24 hrs |
|
Inhibition of class 1 HDAC in human SH-SY5Y cells assessed as increase in acetylation of histone H3 at 0.1 to 1 uM after 24 hrs by Western blot analysis |
30028616 |